Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buddy alerted me to this, same friend alerted $FSLY at $29, stated a position today, and will build around it jmo
* * $NVTA Video Chart 06-22-2020 * *
Link to Video - click here to watch the technical chart video
NVTA up 15% today after Motley Fool recommendation. Shorts are holding 20% of shares so this surge could last a couple of days as the squeeze gains momentum.
News: $NVTA Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias
SAN FRANCISCO , Dec. 10, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™ , an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symp...
Got this from NVTA - Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias
News: $NVTA Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease
PHILADELPHIA , Nov. 15, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced Invitae Discover , a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the...
Got this from NVTA - Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease
Looks like that article was on point. Thanks. Good day.
$NVTA bears and bulls Invitae Corporation Nyse Nvta Short Squeeze
News: $NVTA Invitae to Acquire Clear Genetics
SAN FRANCISCO , Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Us...
In case you are interested NVTA - Invitae to Acquire Clear Genetics
News: $NVTA University of Vermont Health Network begins offering Genomic DNA Testing
BURLINGTON, Vt ., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks...
Got this from NVTA - University of Vermont Health Network begins offering Genomic DNA Testing
Happy here since $18. The science is good here. I am betting on a buy out myself.
In my opinion, today is just the beginning for pps collapsible at NVTA
Pump job is Failing MISERABLY here..BIG DROP COMING.
AL says NVTA TP is $100
https://citronresearch.com/
I can't answer that. It could happen fast and then again, it could
take a little time.
The one thing that is certain is
THAT IT WILL HAPPEN.
I wonder if there is a little time left to sell before the huge DROP.
DAMS Consulting says shorts are getting ready to blast
this stock. If you are long be VERY CAREFUL.
DAMS Consulting
@DAMSConsulting
$NVTA hearing rumor that Short sellers are going to blast this stock If your long Be very careful I have zero interest story going around NYC trading desk
https://twitter.com/DAMSConsulting/status/1158396926737485824
Pump job is Failing MISERABLY here..BIG DROP COMING.
19.50 first support.
19.00 next support.
16.00 next support.
Low 24's company has no profits either.
Nice analysis went with my theory too.
NVTA just hit 25.00. Downward reversal on Point and Figure charts.
Next support is at 19.50.
Way over priced. Big correction coming.
Agree 100 pct. Way over priced. Free fall coming.
Hitting 25.00 is a sell signal on
the Point and Figure charts.
NVTA over priced garbage. Time to short this puppy back to $10. A 1 trick pony with no profits and little income. The fall is just starting.
News: $NVTA Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy
SAN FRANCISCO , June 17, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio , Inc., a privately held company developing single molecule detection technology...
In case you are interested https://marketwirenews.com/news-releases/invitae-to-acquire-singular-bio-to-help-increase-access-to-genetic-screening-in-early-pregnancy-8367618.html
Real pleased to have enjoyed the SP's astounding growth on NVTA since my last post.
It's compensated for a number of my overly optimistic bio stock decisions.
They elected to sink everything into rapid growth instead to going cash flow positive this round;
so the SP is down a bit...I bought more!
Sure am;
Looks good in the long term...Just look at the growth rates!
You still in this?
It was around 5 or 6$ when i wrote this.
1t's $16.47 just now.
It's continuing to grow just as fast...check out the chart.
Do your DD.
It got pretty darn low there and hasn't come up much.
Given the great growth rate...
It's awfully cheap now.
There's some risk , obviously,
but the upside potential is staggering.
Been wanting to buy, just won't pullback any, and chasing always turns out bad for me...
Yeah: I'm no trader..Research, buy and squat on it is my approach.
My iron sculpture takes up most of my free time. It's real and much more satisfying than trading.
The frictional cost of buying and selling constantly is a real handicap.
I like the biotechs and go for the promising long shots. Figure i'll lose on many of them ,but thus far the few winners have compensated.
I'm probably too old for this stuff, but it's hard to stay away.
Given the overall rate of growth of NVTA, it seems reasonable to plunk yer money down and go do something productive for long stretches.
I believe you are right-- great potential. Eye it carefully each day, particularly yesterday. Currently using E*Trade which doesn't permit off hours trading so typically don't hold ahead of earnings. Already up before could trade this morning so now will wait for a dip.
Good for you, however!
NVTA
Too soon.
$6.60 and up 11% just now..
NVTA continues to grow at an astounding pace
and is a fine long term bet!
Out for now @ $5.67 near the EOD. Chart broke @ 3:15. Good gain for the day. Geo-political and political issues scare me from holding overnight especially after gains.
NVTA
Very nice, was hoping for +10%, but keeps getting stronger as the day goes on. (LABU up ~3%).
NVTA
InVitae +3.7% as Baker Bros. reports 12.6% stake
Apr. 10, 2018 6:36 PM ET|By: Jason Aycock, SA News Editor
InVitae (NYSE:NVTA) is up 3.7% after hours alongside a new 13G filing from Baker Bros. Advisors.
The firm reports a 12.6% passive stake in InVitae. That's based on 53.71M shares of the company outstanding as of March 19, plus 11.11M shares outstanding as part of a public offering (and 1.67M shares in a greenshoe option).
Baker Bros. had previously filed on 13D, but notes it now holds shares "in the ordinary course of business without the purpose of or with the effect of changing or influencing the control of the Issuer and do not hold such securities in connection with or as a participant in any transaction having that purpose or effect."
__________________________________________________
https://seekingalpha.com/news/3344834-invitae-plus-3_7-percent-baker-bros-reports-12_6-percent-stake
NVTA
Up after hours (but can't trade with E-trade account). Baker Bros pick up more shares?
NVTA
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing
Tue April 10, 2018 7:30 AM|PR Newswire|About: NVTA
CHARLOTTE, N.C., April 10, 2018 /PRNewswire/ --
Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company's data being presented this week at the American College of Medical Genetics (ACMG) annual meeting in Charlotte, NC.
https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg
Healthy individuals are increasingly seeking genetic testing to identify their personal risks for inherited conditions such as cancer and cardiovascular disease. An analysis of 1,300 patients tested with a diagnostic-grade genetic screening panel designed for healthy adults found clinically actionable results in 16 percent of patients, predominantly in genes associated with an elevated risk for cancer or cardiovascular disease.
"Healthy adults are increasingly interested in using genetic information to understand their risk of disease and these data show that interest is warranted. But it is essential that consumers receive medically sound testing to assess their risk of diseases like cancer where monitoring and early intervention can be helpful," said Robert Nussbaum, M.D., chief medical officer of Invitae (NVTA). "Talking about genetic screening with a physician or genetic counselor and then using the highest quality testing can help ensure people receive accurate results and, just as importantly, sound medical advice on how to respond to those findings."
Invitae's proactive genetic tests are currently being provided at a number of institutions enabling clinicians to use this type of genetic screening with patients in a variety of clinical settings, including primary care.
In another platform presentation at the meeting, researchers from the company are reporting on an analysis of the frequency of actionable variants in hereditary cancer syndrome genes found in more than 3,000 patients referred for testing for hereditary cardiovascular disorders. Under an IRB-approved protocol that allowed review of de-identified test data, the researchers analyzed genetic testing results for a number of well-known genes associated with increased cancer risk in patients with no known indication for hereditary cancer gene testing. The researchers found that six percent of patients had pathogenic variants in clinically actionable hereditary cancer genes.
"Current ACMG guidelines on secondary findings support providing such information regardless of the original indication for testing," said Dr. Nussbaum, one of the authors of the study. "Our study indicates that one in 16 individuals could receive actionable information from hereditary cancer gene testing even in the absence of personal or family history that would suggest the need for a diagnostic evaluation of cancer risk. The results suggest the importance of screening for medically actionable gene mutations regardless of original indication."
The company's research presentations includes one platform presentation, one plenary presentation, and participation in fourteen posters at the meeting:
Wednesday, April 11
Platform presentation, 5:15 p.m. Eastern:
Secondary Findings in Hereditary Cancer Genes from Multigene Panel Data: A New Frontier Unanticipated by the ACMG
Presenter: Ed Esplin, MD, PhD, FACMG, FACP
Presentation #40
Thursday, April 12
Plenary presentation, 9:30 a.m. Eastern:
An Interlaboratory Study of Complex Variant Detection in Clinical Testing
Presenter: Stephen Lincoln
Poster presentations, 10:00 a.m. – 11:30 a.m. Eastern:
Poster #81: Diagnostic yield analysis of Invitae's metabolic analyte panels
Presenter: Michelle Fox, MS, LCGC
Poster #333: The Paperwork Matters! Phenotypic Information Significantly Impacts Variant Interpretation in Hereditary Cancer Testing
Presenter: Carolina Pardo, PhD
Poster #355: Detection of NF1 variants by NGS Panels with SNV and CNV Identification Exceeds Published Estimates and Improves Clinical Utility
Presenter: Karen Ouyang, PhD, FACMG
Poster #379: Behind the Seizure™: A No-Cost, 125-Gene Epilepsy Panel for Pediatric Seizure Onset Between 2-4 Years
Presenter: Nicole Miller, PhD
Poster #723: Current challenges in the classification of large genetic events affecting TTN
Presenter: Matteo Vatta, PhD, FACMG
Friday, April 13
Poster presentations, 10:30 a.m. – Noon Eastern:
Poster #142: The Clinical Impact of Mutations beyond BRCA1/BRCA2 in Breast Cancer Patients
Presenter: Judith Westman, MD
Poster #166 - Blue Ribbon: Down Syndrome Resources from the National Institutes of Health: Research Projects Supported by the DS-Connect® Registry
Presenter: Melissa Parisi, MD, PhD
Poster #218: ClinGen's GenomeConnect Registry Enables Patient-Centric Data Sharing
Presenter: Juliann Savatt, MS, LGC
Poster #326: Reducing VUS Rates Among Ethnic Groups: Sequencing Smarter, Not Harder
Presenter: Shan Yang, PhD
Poster #458: Quantitative Determination of SMN2 Copy Number using Next Generation Sequencing and Correlation to Disease Severity
Presenter: Sarah Klemm, MS
Poster #572: Are we ready for Telegenetics? Surveying the current landscape among ACMG members
Presenter: Shweta Dhar, MD, MS
Poster #622: Misattributed Paternity as an Unanticipated Finding During Exome/Genome Sequencing: Current Clinical Laboratory Practices and an Opportunity for Professional Recommendation Development
Presenter: Celeste Eno, PhD
Poster #628: Improved Diagnostic Confirmation of Newborn Screening Conditions by Next-Generation Sequencing: A Collaboration Between Laboratory and Clinician
Presenter: Michelle Fox, MS, LCGC
Poster #666: Multigene Panel Screening for Hereditary Disease Risk in Healthy Individuals
Presenter: Eden Haverfield, PhD, FACMG
About Invitae Corporation
Invitae Corporation (NYSE: NVTA) is a genetic information company. Invitae's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the utility of proactive genetic screening; the increase in healthy individuals seeking genetic testing to identify personal risks for inherited conditions; and the importance of assessing secondary findings in genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's ability to continue to generate substantial demand for its tests: the company's ability to compete; the company's history of losses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2017. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Source: Invitae Corporation
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
https://c212.net/c/img/favicon.png?sn=SF61319&sd=2018-04-10 View original content with multimedia:http://www.prnewswire.com/news-releases/invitae-research-highlights-utility-of-proactive-genetic-screening-importance-of-assessing-secondary-findings-in-genetic-testing-300626957.html
SOURCE Invitae Corporation
__________________________________________
NVTA
Assessing Invitae's Flub This Week
Apr. 1, 2018 10:22 AM ET|9 comments |About: Invitae (NVTA)
Never apologize, mister, it’s a sign of weakness.” ? John Wayne
The market has been volatile since early February, especially in the high beta parts of the market like biotech and small caps in general. For those needing to add 'balance' to their portfolio, I do recommend Tim Plaehn; a friend & colleague of mine at Investors Alley as well as a contributor here on SeekingAlpha. Tim runs the Dividend Hunter newsletter which offers a solid & diverse selection of attractive high yield plays. The service is now over 6,500 active subscribers and can be had HERE for the rock bottom price of $49 (It usually is $99) for the first year. There are few better bargains around. He also has a free report on five dividend stocks he likes in 2018, which can be downloaded gratis HERE.
Click link for chart/table
Because no retreat from the world can mask what is in your face.” ? Gregory Maguire,
I have started to believe in recent years that the most important executive at most small Tier 3 and Tier 4 biotech/biopharma concerns is not the CEO. It is also not the Chief Medical Officer or the head of Marketing. It is the CFO.
Planning for and funding operational needs while clearly communicating and keeping to plans with shareholders are paramount to credibility (and one’s stock price). Doing this while ensuring not placing the company in a position that puts it behind the ‘eight ball’ in capital raise negotiations can be a tricky balancing act. Those that do it well can enhance the valuation on their stock. Doing it incompetently, can erode stock value.
We saw that again this week as the stocks of Sorrento Therapeutics (SRNE) and genetic testing concern Invitae (NVTA) because of poorly received capital raises. Meanwhile, investors barely batted an eye on similar raises that were well received with Xencor (XNCR) and Heron Therapeutics (HRTX). We will be doing an exclusive 'deep dive' around Sorrento later this week for members of The Biotech Forum. In today's instablog post, we will take a look at Invitae's flub.
The company decided to raise some $55 million this week via a secondary offering. It was not the amount of the raise that set investors, it was the price ($4.50 a share) of the offering. Given where the stock ($7.02 a share) started the week, it seemed more of a 'fire sale' than a capital raise.
Click link for chart/table
Invitae was somewhat under the gun as it has just over $75 million in cash and marketable securities on the balance sheet at the end of 2017. Cash used in operating activities in 2017 amounted to $97.7 million which gave it at least three quarters of 'cash burn' left. Quarterly cash burn should start to come down markedly as samples/sales ramp up significantly in the year ahead. My opinion is that the company did a very poor job in negotiating the terms of this deal.
Click link for chart/table
Source: Company Presentation
As can been seen in the chart above, the company is in the midst of a major period of growth. Management has guided they expect at least $120 million in revenue in FY2018 after just less than $70 million in FY2017. They also expect to test at least 250,000 samples and continue to bring the cost per test down.
Click link for chart/table
Source: Company Presentation
Invitae has a huge secular tailwind behind it as the genetic testing market is expected to roughly triple to a ~$10 billion annual pace over the next five to six years. I also think eventually all the testing data the company is warehousing will turn into a valuable data analytics asset as well.
Image result for buy-write strategy I decided to 'hold my nose' and double down on Invitae using Buy-Write orders to help mitigate some risk late this week. I also find it somewhat comforting that Julian Baker of the Baker Bros. bought just over $5 million of the secondary offering. If one of the best investors in the healthcare space can get over his disappointment on how this capital raise was conducted, I guess I can as well.
It is the bungled crime that brings remorse.” ? P.G. Wodehouse, Love Among the Chickens
Image result for investor toolboxFor those that want to learn about more advanced option strategies to put in their investor 'toolbox', I highly recommend the free 30 minute report and 7 minute video my Investors Alley's colleague Jay Soloff has put together. Jay has been teaching about and using option strategies successfully for two decades. The free video and report can be downloaded HERE
__________________________________________
https://seekingalpha.com/instablog/498952-bret-jensen/5138357-assessing-invitaes-flub-week
NVTA
The big loser is top holder because all shares would be bought substantially above $4.50. A quick calculation would be they paid ~$9.52 so they lost about $35M. Would assume they are buying them up today unless they had already unloaded and that was the reason for the offering.
"Brothers Advisors, LLC 7,288,300 Dec 30, 2017 13.57% $69,530,381"
NVTA
This Explains Why Invitae Is Sinking Today
Brian Feroldi, The Motley Fool
Motley FoolMarch 27, 2018
What happened
In response to the high-growth genetic testing company announcing plans for a secondary common stock offering, shares of Invitae (NYSE: NVTA) fell 17% as of 10:40 a.m. EDT on Tuesday.
So what
Invitae plans to raise $50 million through a secondary common stock. As usual, the underwriters of the deal are also being granted an option to purchase up to an additional $7.5 million worth of stock at the offering price. When combined, this transaction could raise up to $57.5 million before subtracting fees.
For perspective, Invitae's market cap right now is about $320 million, so this deal could dilute current shareholders by up to 18%.
The timing of this capital raise is a bit of a head-scratcher because Invitae's stock has now fallen by about 34% since the start of 2018. What's more, the company just increased its credit facility by $20 million in February, so you wouldn't think that a common stock offering would be necessary so soon.
Given the potential dilution, it isn't hard to figure out why Wall Street isn't happy about today's update.
Businessman with coins falling through his hands
More
Image source: Getty Images.
Now what
Invitae burned through $98 million in 2017 and ended the year with about $76 million in cash. When adding in the recent credit facility expansion and today's common stock offering, the company should now have access to enough capital to keep it in hypergrowth mode for at least another year.
On the flip side, it still has a long way to go before it starts to reach profitability, so today's capital raise isn't likely to be its last. For that reason, my plan is to keep this intriguing company as a watchlist idea for the foreseeable future.
_________________________________________________
https://finance.yahoo.com/news/explains-why-invitae-sinking-today-155600515.html?_fsig=l4uoFgAeA5AgCaxyZB14yg--
NVTA
Back in NVTA @ $6.20. Seem to recall that after the last offering didn't stay down very long (Baker Bro is huge holder).
NVTA
FWIW, I rarely make comments when not currently invested in a stock; keeps me more honest and appeases my conscience. Hence my statements of when I enter and leave.
NVTA
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
180
|
Created
|
01/09/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |